DataMeds AI, Inc.
No SEC Form 4 filings for $MEDS in the last 30 days.
DataMeds AI, Inc. (NASDAQ:MEDS) reiterated that Aug. 7, 2026 is the record date for a 50:1 Dream Bowl Meme Coin token to DataMeds common shares dividend ratio, according to the company. The token is listed on Biconomy, and the company said it intends to pursue fail-to-deliver notices aggressively.
DataMeds AI (MEDS) said it signed an amended letter of intent to gain control of Tollo Health, license QOLPOM-related IP from EOS Technology Holdings and Scilex, and expand its Datavault AI Health license. Consideration is in common stock only. EOS, Scilex, Datavault AI and HealthBridge Advisors are expected to hold about 84.6% post-closing, Fortitude about 5%, subject to adjustments. Closing depends on definitive deals, financing, approvals and Nasdaq.
DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED LETTER OF INTENT July 29, 2026 This Amended and Restated Letter of Intent (this “ LOI ”) sets forth our current proposal with regard to the proposed combination (the “ Transaction ”) of DataMEDS AI, Inc., a reporting
Over the past 7 days, alphai's AI scored 4 news stories mentioning MEDS (DataMeds AI, Inc.). Coverage has skewed bullish: 2 bullish, 2 neutral, and 0 bearish.
Recent MEDS coverage spans corporate actions, mergers & acquisitions and financial news.
The update is a near-term corporate action catalyst for MEDS tied to a token dividend ratio and record date.
The LOI is a fresh M&A control and IP licensing catalyst for MEDS, but it is not yet a definitive deal and remains subject to approvals and Nasdaq requirements.
The 8-K discloses a binding LOI with legally enforceable provisions tied to a transaction that reshapes MEDS’s IP portfolio and capital structure.
Near-term upside case is incremental revenue visibility from new DTC products plus potential control premium if the Tollo Health acquisition closes. Downside is execution and regulatory/clinical uncertainty around supplement/medical-food claims and the non-binding LOI.
Near-term upside case is incremental revenue visibility from new DTC products plus potential consolidation via a controlling-interest acquisition. Key risk is the LOI is non-binding and the products are supplements/medical foods with uncertain clinical and regulatory traction.
alphai scores every news story that mentions MEDS with an AI model for sentiment and relevance, and aggregates insider trades from DataMeds AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DataMeds AI, Inc. (NASDAQ:MEDS) reiterated that Aug. 7, 2026 is the record date for a 50:1 Dream Bowl Meme Coin token to DataMeds common shares dividend ratio, according to the company. The token is listed on Biconomy, and the company said it intends to pursue fail-to-deliver notices aggressively.
2 min readDataMeds AI (MEDS) said it signed an amended letter of intent to gain control of Tollo Health, license QOLPOM-related IP from EOS Technology Holdings and Scilex, and expand its Datavault AI Health license. Consideration is in common stock only. EOS, Scilex, Datavault AI and HealthBridge Advisors are expected to hold about 84.6% post-closing, Fortitude about 5%, subject to adjustments. Closing depends on definitive deals, financing, approvals and Nasdaq.
1 min readDataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED LETTER OF INTENT July 29, 2026 This Amended and Restated Letter of Intent (this “ LOI ”) sets forth our current proposal with regard to the proposed combination (the “ Transaction ”) of DataMEDS AI, Inc., a reporting
7 min readDataMeds AI (NASDAQ:MEDS) said its wholly owned Corexa Pharmacy has started DTC distribution of Tollo Health’s Tollovid, a 3CL protease inhibitor dietary supplement, and Galactovid, a medical food for galectin-1/3 associated viral infections. DataMeds also disclosed a non-binding letter of intent to acquire a controlling interest in Tollo Health.
4 min readDataMeds AI (NASDAQ:MEDS) said its wholly owned Corexa Pharmacy has started DTC distribution via CorexaRx of Tollo Health’s Tollovid (a 3CL protease inhibitor dietary supplement) and Galactovid (a medical food for galectin-1/3 associated viral infections). DataMeds AI also disclosed a non-binding LOI to acquire a controlling interest in Tollo Health, subject to definitive agreements and closing conditions.
4 min readDatavault AI (NASDAQ:DVLT) said it amended its definitive agreement with DataMeds AI (NASDAQ:MEDS) to expand a PharmacyChain blockchain technology licensing relationship into unencumbered commercial healthcare, healthspan and wellness uses. Datavault AI will receive common shares worth about 19.9% of DataMeds’ stock at closing, replacing preferred shares for tax optimization.
3 min readDatavault AI (NASDAQ: DVLT) said it expanded its licensing agreement with DataMeds AI (NASDAQ: MEDS) to commercial healthcare, healthspan and wellness, using PharmacyChain blockchain-related technology for patient-controlled data access and tokenization. DVLT will receive common shares equal to about 19.9% of MEDS’ outstanding stock at closing, replacing preferred shares.
3 min readDataMeds AI (NASDAQ:MEDS) said it amended its licensing agreement with Datavault AI (NASDAQ:DVLT) to expand PharmacyChain blockchain-related licensing from pharmaceutical distribution to all unencumbered commercial healthcare, healthspan and wellness uses. The deal is tied to a pending multi-party combination and includes DVLT receiving common shares worth about 19.9% of MEDS at closing.
6 min readBiotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
6 min readWellgistics Health, Inc. (NASDAQ:WGRX) said it completed its corporate name change to DataMeds AI, Inc. and will begin trading on NASDAQ Capital Market under ticker MEDS on July 22, 2026. The company links its blockchain smart contracts and EinsteinRx AI to a patient data ecosystem and targets GLP-1 muscle loss and Long COVID.
4 min read
